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Objectives: To conduct a cost-effectiveness analysis of panitumumab plus mFOL-
FOX6 versus bevacizumab plus mFOLFOX6 as first-line treatment (FLT) of metastatic 
colorectal cancer (mCRC) patients with wild-type RASin the Greek health care set-
ting. MethOds: An existing Markov model consisting of seven health states was 
adapted from the public third-party-payer perspective. Both efficacy and safety data 
considered in the model were extracted from the PEAK trial and other published 
studies. Utility values were also extracted from the literature. Direct medical costs 
consisting of drug-acquisition costs for FLT, administration costs, subsequent ther-
apy costs and other medical costs were incorporated into the model and reflect the 
year 2014. Primary outcomes were patient survival (life-years), quality-adjusted life 
years (QALYs) and the incremental cost-effectiveness ratio (ICER) per QALY gained. 
Probabilistic sensitivity analysis (PSA) was conducted to account for uncertainty 
and variation in the parameters of the model. Results: The analysis showed that 
panitumumab plus mFOLFOX6 produced greater discounted survival and quality 
adjusted survival by 0.87 LYs and 0.65 QALY benefit in relation to bevacizumab plus 
mFOLFOX6. The total lifetime cost was € 75,200 and € 52,736 for panitumumab and 
bevacizumab plus mFOLFOX6, respectively. This difference was mainly attributed 
to the higher acquisition cost of panitumumab compared to bevacizumab during 
the pre-progression health state (€ 32,223 and € 14,730 respectively). Incremental 
analysis showed that panitumumab plus mFOLFOX6 was more effective and more 
costly than bevacizumab plus mFOLFOX6 resulting in an ICER equal to € 34,644 
per QALY gained. PSA revealed that the probability of panitumumab plus mFOL-
FOX6 being cost-effective over bevacizumab plus mFOLFOX6 was 81.5% at the pre-
determined threshold of € 51,000 per QALY gained (3 times the GDP per capita of 
Greece). cOnclusiOns: The results suggest that panitumumab plus mFOLFOX6 
may be a cost-effective alternative relative to bevacizumab plus mFOLFOX6 as FLT 
of mCRC patients with wild-type RASin Greece.
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Objectives: To conduct an economic evaluation comparing pegfilgrastim with 
filgrastim or lenograstim used either in an 11-day regimen or in a 6-day regimen for 
the prophylaxis of febrile neutropenia (FN) in breast cancer patients, in the Greek 
health care setting. MethOds: A cost-effectiveness model was locally adapted from 
the public third-party-payer perspective. Efficacy and utility values extracted from 
published studies were considered in the model. The analysis was conducted for a 
6-cycle horizon, to reflect the common clinical practice in Greece. Drug acquisition 
costs, administration costs and FN management reimbursed costs were considered 
(in € 2014). The outcomes of the model were the incremental cost per additional FN 
event avoided and per QALY gained (ICER) of pegfilgrastim to its comparators. The 
ICERs were evaluated at the predetermined willingness-to-pay threshold of € 34,000/
QALY gained. Results: The incremental cost per additional FN event avoided with 
pegfilgrastim ranged between € 11,015 and € 27,079 compared to 11-day regimens of 
originator and a biosimilar filgrastim respectively, while pegfilgrastim was found 
to be dominant compared to the 11-day regimen of lenograstim. Comparing peg-
filgrastim with the 6-day regimen of filgrastim and lenograstim, it was found that 
the ICER per additional FN event avoided ranged between € 9,538 and € 15,207 in case 
of lenograstim and biosimilar filgrastim respectively. Similarly, cost-utility analysis 
revealed that pegfilgrastim was cost-effective over 11-day and 6-day regimens of 
originator filgrastim with ICERs of € 11,065 and € 19,942/QALY gained, respectively. 
Compared to lenograstim, pegfilgrastim was found to be dominant over the 11-day 
regimen and cost-effective over the 6-day regimen (ICER: € 15,546). cOnclusiOns: 
Our findings suggests that pegfilgrastim for the prophylaxis of chemotherapy-
induced FN in breast cancer patients is associated with greater health benefit and 
lower cost over 11-day use of lenograstim, while it is a cost-effective option over 
either the 6-day or the 11-day regimen of biosimilar filgrastim, in Greece.
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Objectives: Hungarian adaptation of global cost-effectiveness models of vismod-
egib vs. standard of care (SOC) in the treatment of locally advanced or symptomatic 
metastatic basal cell carcinoma (laBCC and mBCC). MethOds: Global Markov-
models were developed to compare the cost-effectiveness of vismodegib vs. SOC 
in patients with laBCC or mBCC. The model inputs were based on the pivotal phase 
II clinical study (ERIVANCE). Health state utility values were based on a time trade 
off study. To support the reimbursement dossier submission, the adaptation of the 
global cost-effectiveness models was conducted. The costs and resource use were 
recalculated based on a questionnaire survey with Hungarian health care profes-
sionals. In the model there were two treatment arms, vismodegib and SOC. The 
model had three states, progression-free, progressed and death. For progression-free 
survival (PFS) and overall survival (OS) the results of the phase II clinical trial were 
used in the vismodegib arm of the model. Originally on the SOC arm the model 
calculated with mortality data of the general population, due to lack of relevant data 
on the PFS and OS of patients with advanced BCC. Therefore, a research (Delphi-
panel survey) was conducted to estimate the OS of patients with laBCC and mBCC, 
treated with SOC. Results: According to the Delphi-panel survey the median OS for 
patients with laBCC and mBCC was 48 months and 24 months, respectively, on the 
SOC arm. The average time spent in progression-free health state is longer with vis-
5-year time horizon, PFS data assessed by independent review, drug doses adjusted 
by relative dose intensity reported in COMPARZ trial and a discount rate of 3% for 
costs and outcomes. Results were expressed as € 2014. Deterministic (10-year time 
horizon, discount rates 0 and 5%, PFS assessed by investigator, and plenty-doses) 
and probabilistic sensitivity analyses were conducted to determine the robustness 
of the results. Results: In the base case analysis, pazopanib showed as a dominant 
alternative, yielding more quality of life adjusted years (0.081) and less total costs 
(€ 6,671) vs. sunitinib. Base-case results were robust in the alternative scenarios 
examined via deterministic sensitivity analyses. In the probabilistic sensitivity 
analysis (PSA), a 67% of the simulations were plotted in the dominant quadrant of 
the cost-effectiveness plane. cOnclusiOns: In the light of the present analysis, 
pazopanib should be considered as a dominant alternative vs. sunitinib in the first-
line mRCC treatment from the Spanish National Healthcare perspective.
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Non-small-cell lung cancer (NSCLC) is the most common type of cancer repre-
senting 18.2% of all cancer deaths around the world and in Mexico the estimated 
mortality rate is 13.4 by 100,000 patients. Objectives: Evaluate gefitinib as first 
and second line treatment of locally advanced or metastatic NSCLC compared to 
available treatment alternatives in Mexico. MethOds: A two-way analysis was per-
formed: (1) For the first-line treatment in patients with Epidermal Growth Factor 
Receptor Inhibition in Mutation-Positive Non–Small-Cell Lung Cancer (EGFR M+ 
NSCLC) a cost-minimization analysis was used comparing gefitinib versus erlotinib 
(Kim ST, 2012), also a Markov model was developed to perform a cost-effectiveness 
analysis evaluating gefitinib versus carboplatin+paclitaxel (Mok TS, 2009), with 
efficacy measure Progression-free survival (PFS); and (2) For patients in a second-
line NSCLC treatment, regardless of EGFR mutation, a cost-minimization analy-
sis was conducted comparing gefitinib versus docetaxel and pemetrexed (Hanna 
N, 2004) (Kim ES, 2008). The costs were obtained from institutional sources. An 
exchange rate of $13.12 MXN per USD was used. Sensitivity analyses were per-
formed in order to test the robustness of the model. Results: For first-line treat-
ment, gefitinib was a cost-saving alternative respect to erlotinib, obtaining a cost 
differential of $9,710 USD in favor of gefitinib. To the same patients gefitinib com-
pared to carboplatin plus paclitaxel generated an additional cost of $2,361 USD 
per patient, with additional PFS of 0.37 years and an ICER of $7,023. For second-
line treatment gefitinib had a lower cost compared to pemetrexed and docetaxel, 
generating a saving per patient of $927 USD and $21,346 USD respectively. Robustness 
of results was confirmed by additional deterministic and probabilistic sensitivity 
analysis. cOnclusiOns: The use of gefitinib for the treatment of locally advanced or 
metastatic NSCLC is a cost-saving alternative compared to erlotinib, pemetrexed and 
docetaxel, and also cost-effective compared to carboplatin plus paclitaxel.
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Objectives: This study aimed to estimate the cost-effectiveness of Ofatumumab 
plus Chlorambucil (OChl) compared with Chlorambucil (Chl) for patients with 
Chronic Lymphocytic Leukemia for whom fludarabine-based therapies are consid-
ered inappropriate, from the perspective of the publicly funded health care system 
in Canada. MethOds: A semi-Markov based decision model was developed with a 
lifetime time horizon. The model comprised two distinct phases. The preprogression 
phase was based on the overall response rates (ORR), progression free survival (PFS) 
and overall survival (OS) observed in the COMPLEMENT-1 trial. The postprogression 
phase was based on Canadian treatment practices, treatment patterns identified 
in clinical guidelines and published literature. The incremental cost per quality-
adjusted life year (QALY) gained was computed using model-estimated first- and 
subsequent-line treatment costs, general disease management costs, and QALYs 
based on health-state preference utility weights. Results: The discounted, lifetime 
health and economic outcomes estimated by the model showed that first-line treat-
ment with OChl in comparison with Chl in the target population led to an increase in 
QALYs (0.41) and an increase in total costs (CAD $27,850), resulting in an incremental 
cost-effectiveness ratio (ICER) of CAD $68,672/QALY gained. Various scenario analyses 
indicated that the cost-effectiveness results were sensitive to the time horizon, the 
method used to assess response, and the extrapolation of OS treatment effect beyond 
the trial period. One way and probabilistic sensitivity analyses aligned with the results 
of the base-case analysis. cOnclusiOns: The base-case results indicate that the 
improved ORR, PFS, and OS for OChl in comparison with Chl translate to improved 
long-term health outcomes. The analysis found that the ICER for OChl versus Chl in 
the target population was CAD $68,672/QALY gained. A variety of sensitivity and sce-
nario analyses confirmed that the model’s cost-effectiveness estimates were robust.
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sitivity analysis (PSA) was run with thousand repetitions and a one-way sensitiv-
ity analysis was calculated showing its results in a tornado chart. Results: The 
model showed that everolimus + exemestane results in 0.74 progression free years 
gained with an incremental cost of $18.6 million (MM) resulting in an incremental 
cost-effectiveness ratio (ICER) of $26 MM. The PSA showed that the ICER is within 
the range recommended by WHO (1-3 GDPs per capita) in 71% of cases (Currently 
the GDP per capita in Chile is $10 MM). cOnclusiOns: This analysis showed 
that using everolimus plus exemestane in patients with ER +, HER2- advanced 
breast cancer who have failed on NSAIs is a cost-effective option according to 
WHO recommendations.
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Objectives: Slovakia is a country with high incidence and mortality of cervical 
cancer (CC). Despite the improvements in screening (22.9% coverage rate), the CC 
incidence has increased over the past 30 years in Slovakia. Human Papillomavirus 
(HPV) vaccination could help to reduce this CC burden. The objective of this analy-
sis was to assess the cost-effectiveness of adding the AS04-adjuvanted HPV-16/18 
vaccine (AS04V), using a 2-dose administration schedule, to the current CC screen-
ing programme in Slovakia. MethOds: A previously published Markov cohort 
model, reproducing the natural history of HPV infection, the impact of screening 
and vaccination, was adapted to the Slovakian settings. Local data on health care 
costs of pre-cancer lesions and CC, obtained from the expert panel, were used. 
Transition probabilities and utilities were estimated from published data. Costs 
were from a health care payer perspective. The incremental CC cases avoided, cost, 
quality-adjusted life-years (QALYs) and resulting cost-effectiveness ratio (ICER) 
of AS04V added to the current CC screening programme versus the current CC 
screening in Slovakia was estimated. The base case assumes a 100% vaccination 
coverage among 12-year-old girls (N= 24,859). A discount rate of 5% was used. 
Univariate sensitivity analyses were carried out on key parameters. Results: 
Compared to screening alone, adding AS04V to the current screening programme 
was estimated to reduce the lifetime CC cases by 328 at an ICER of 11,621 € /
QALY gained. Compared to the official cut-off of 19,320€ /QALY gained, it can be 
considered as cost-effective. Undiscounted analysis shows that AS04V generates 
more QALYs with similar cost versus screening alone (ICER= 5€ /QALY gained). 
Parameters most driving the results were discount rate, vaccine efficacy and dura-
tion of protection. cOnclusiOns: AS04V vaccination of 12-year-old girls in a 
2-dose schedule was estimated to be a cost-effective CC prevention strategy in 
Slovakia.
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Objectives: To evaluate the cost-effectiveness of everolimus plus exemestane 
(EVE+EXE) versus chemotherapy agents [docetaxel (DOC), vinorelbine (VIN), dox-
orubicin (DOX) and capecitabine (CAPE)] for the treatment of hormone receptor 
positive (HR+) HER2 negative (HER2-) advanced or metastatic breast cancer in the 
United Kingdom (UK). MethOds: A partitioned survival model was developed to 
compare treatment with EVE+EXE versus DOC, VIN, DOX and CAPE in patients with 
ER+ HER2- metastatic breast cancer over a 10-year time horizon from a UK NHS 
perspective. Progression-free survival and overall survival for EVE+EXE were taken 
from the BOLERO-2 trial. Log-logistic functions were used to extrapolate trial data 
beyond the follow-up period. In the absence of head-to-head evidence comparing 
EVE+EXE versus chemotherapy a naïve chained comparison was conducted with 
the link between EVE+EXE established via tamoxifen using the Bucher method. 
A class effect was assumed for the four chemotherapy agents. Background health 
state and terminal care resource use were derived from NICE Clinical Guideline 81. 
Drug costs were taken from the British National Formulary. Utilities for stable and 
progressive states were obtained from the literature (Lloyd et al. 2006). Results: 
Over a ten year time horizon, EVE+EXE led to a life expectancy of 3.55 years, com-
pared to 1.88 for chemotherapy agents (DOC, VIN, DOX and CAPE). EVE+EXE resulted 
in 2.06 QALYs, compared to 0.95 for chemotherapy agents. Total costs were £48,085 
for EVE+EXE compared to £31,835 vs. DOC, £25,021 vs. VIN, £23,743 vs. DOX and 
£21,851 vs. CAPE. The incremental costs per QALY were £14,550 vs. DOC, £20,653 vs. 
VIN, £21,797 vs. DOX and £23,491 vs. CAPE. Results were most sensitive to changes 
in PFS for chemotherapy and disease related costs. cOnclusiOns: Everolimus in 
combination with exemestane is a cost effective option compared with commonly 
used chemotherapeutic agents (docetaxel, vinorelbine, doxorubicin and capecit-
abine) in UK clinical practice.
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Objectives: Bevacizumab in combination with carboplatin/paclitaxel (BCP) was 
approved to be the first-line therapy of advanced NSCLC due to its high clini-
cal efficacy. However, economic effectiveness of BCP has been controversial. This 
study aimed to estimate the cost-effectiveness of BCP versus PC in treatment of 
advanced NSCLC patients from patients’ perspective in Vietnam. MethOds: A 
modegib therapy than with SOC for both, laBCC and mBCC patients. cOnclusiOns: 
Vismodegib could provide an effective treatment for this therapeutic area with high 
rate of unmet need. During the adaptation process Delphi-panel surveys seemed 
to be an appropriate method to earn consensus statement to ensure estimation 
and help interpretation.
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Objectives: The United Kingdom (UK) runs a successful human papillomavirus 
(HPV) girls vaccination programme. Debate is ongoing on the value of including 
boys in the programme. This study aims at quantifying the potential value associ-
ated with genital warts (GW) and HPV-related cancer prevention in UK males and 
females based on a willingness-to-pay threshold of £20,000 per quality-adjusted 
life-years (QALY) gained, representing the potential value a government places 
on the prevention of these diseases. MethOds: A static vaccine steady-state 
(VSS) population model, stratified by age, with a 1-year time horizon, replicated 
the incidence of GW and HPV-related cancers in females (cervical (CC), anal (AC), 
vulvar (VuC), vaginal (VaC), oropharyngeal (OP)) and males (penile (PC), AC and 
OP) pre-vaccination and at VSS. Data were retrieved from UK cancer registries, 
sexually transmitted diseases reports and HPVCentre. Costs and utilities were 
identified from the literature. The VSS vaccine effectiveness for GW and HPV-
related cancers was estimated combining efficacies (AS04-adjuvanted HPV-16/18 
vaccine for cancers; HPV-6/11/16/18 vaccine for GW) weighted by vaccine-types 
(HPV-6/11/16/18) and non-vaccine types (HPV-31/33/35/39/45/51/52/56/58/59) HPV 
distribution. Costs and QALYs were discounted at 1.5%. Per-course vaccine cost-
effective price (vCE-p) was determined by increasing vaccine course price until 
£20,000 per incremental QALY gained at VSS was reached. Sensitivity analyses 
on key variables were performed. Results: The vCE-p in women (men) was: CC 
£790, OP £20 (£57), AC £123 (£77), VaC £37, VuC £58, (PC £40), GW £26 (£27). Total 
value of cancer prevention in women (men) was £1,027 (£173), a proportion of 6: 
1. The value of CC alone is 4.5 times larger than the total value of cancer preven-
tion in men. Sensitivity analyses showed results were robust while influenced by 
potential herd protection. cOnclusiOns: The vCE-p was estimated to be up to 
6 times higher in women than in men due to the higher burden and frequency of 
HPV-related cancers in women.
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Objectives: to evaluate the cost-effectiveness of aprepitant as add-on ther-
apy to the standard Egyptian regimen in patients receiving highly emetogenic 
therapy. MethOds: A decision tree model was developed based on the Egyptian 
clinical practice, and was derived from published sources. This decision analyti-
cal model was constructed to assess the costs and consequences associated with 
aprepitant containing regimen compared with standard therapy for Chemotherapy-
Induced Nausea and Vomiting. The clinical parameters were derived from a ran-
domized trial previously published. The utility of the health states was derived 
using the available published data. Direct medical costs were obtained from the 
third party payer tariff in Egypt. Deterministic sensitivity analyses were conducted. 
All costs (in 2014 EGP) and outcomes were discounted at 3.5% annually. Results: 
The total quality-adjusted life-years (QALYs) of adding aprepitant to the standard 
regimen was estimated to be 0.0082, whereas that of the standard regimen was 
estimated to be 0.0072 (with a net difference of 0.001QALYs). The total costs for 
aprepitant plus standard regimen and standard regimen alone were EGP 414.25 
and EGP 346.62 respectively (with a net difference of EGP 67.63). Thus the incre-
mental cost-effectiveness ratio (ICER) for aprepitant was EGP 66,004/QALY gained. 
The probability of complete protection and incomplete response of both arms 
were found to have the greatest effect on the results. cOnclusiOns:  The present 
study concludes that adding aprepitant to the standard regimen is cost effective 
based on the threshold stated by world health organization (3xGDP/capita) for 
patients with severe vomiting after chemotherapy.
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Objectives: To evaluate the cost-effectiveness of everolimus plus exemes-
tane in patients with ER+, HER2- advanced breast cancer, who have failed on 
NSAIs. MethOds: A Markov model was developed with monthly cycles and a 
time horizon of five years. The model compares progression free survival (PFS) of 
exemestane + everolimus (EVE+EXE) to exemestane monotherapy (EXE). Transition 
probabilities for PFS of EVE+EXE and EXE were based on BOLERO-2 study and calcu-
lated using a fitted Weibull distribution. The R-squared values for the Weibull fits 
were 0.998 and 0.990 for EVE+EXE and EXE alone respectively. The Weibull param-
eters used in the model were: 0.067 and 1.118 for EVE+EXE and 0.191 and 1.006 for 
EXE. Costs considered included drugs and cost of treating neutropenia (other AEs 
are not covered by the National Formulary). The analysis was designed from the 
perspective of the Chilean Public Healthcare. Results are shown in 2014 Chilean 
pesos. A 5% discount rate for costs and efficacies was applied. A probabilistic sen-
